Selective inhibitors of bromodomain have received a significant amount of attention from recently due to their outstanding efficacy demonstrated in multiple cancer models, with several of these inhibitors already advancing to clinical trials recently, which indicates a great potential of TRIM proteins in cancer treatment [13, 14]. The gene discussed is TRAT1; the disease is cancer.